147 related articles for article (PubMed ID: 37734447)
1. Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature.
Lu Z; Afzal M; Shirai K
Transpl Immunol; 2023 Dec; 81():101932. PubMed ID: 37734447
[TBL] [Abstract][Full Text] [Related]
2. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
O'Connell KA; Schmults CD
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
[TBL] [Abstract][Full Text] [Related]
5. Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient.
Eleftheriadis T; Samaras I; Spanos A; Kotsakis A; Stefanidis I
Exp Clin Transplant; 2023 Jun; 21(6):534-536. PubMed ID: 37455472
[TBL] [Abstract][Full Text] [Related]
6. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
Khaddour K; Musiek A; Cornelius LA; Dehdashti F; Westervelt P; Fields R; Ansstas G
J Immunother Cancer; 2019 Dec; 7(1):338. PubMed ID: 31801591
[TBL] [Abstract][Full Text] [Related]
7. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC
Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872
[TBL] [Abstract][Full Text] [Related]
8. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
Hanania HL; Lewis DJ
J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
[TBL] [Abstract][Full Text] [Related]
10. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Murakami N; Mulvaney P; Danesh M; Abudayyeh A; Diab A; Abdel-Wahab N; Abdelrahim M; Khairallah P; Shirazian S; Kukla A; Owoyemi IO; Alhamad T; Husami S; Menon M; Santeusanio A; Blosser CD; Zuniga SC; Soler MJ; Moreso F; Mithani Z; Ortiz-Melo D; Jaimes EA; Gutgarts V; Lum E; Danovitch GM; Cardarelli F; Drews RE; Bassil C; Swank JL; Westphal S; Mannon RB; Shirai K; Kitchlu A; Ong S; Machado SM; Mothi SS; Ott PA; Rahma O; Hodi FS; Sise ME; Gupta S; Leaf DE; Devoe CE; Wanchoo R; Nair VV; Schmults CD; Hanna GJ; Sprangers B; Riella LV; Jhaveri KD;
Kidney Int; 2021 Jul; 100(1):196-205. PubMed ID: 33359528
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
Vidovic D; Simms GA; Pasternak S; Walsh M; Peltekian K; Stein J; Helyer LK; Giacomantonio CA
Front Immunol; 2021; 12():678028. PubMed ID: 34122442
[TBL] [Abstract][Full Text] [Related]
12. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
Paoluzzi L; Ow TJ
Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
14. Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report.
Murianni V; Cerbone L; Rescigno P; Catalano F; Damassi A; Cremante M; Gandini A; Puglisi S; Pesola G; Banna GL; Buti S; Signori A; Fornarini G; Rebuzzi SE
Immunotherapy; 2022 Dec; 14(18):1419-1427. PubMed ID: 36597723
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
Campbell SB; Walker R; Tai SS; Jiang Q; Russ GR
Am J Transplant; 2012 May; 12(5):1146-56. PubMed ID: 22420843
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.
Portuguese AJ; Tykodi SS; Blosser CD; Gooley TA; Thompson JA; Hall ET
J Natl Compr Canc Netw; 2022 Apr; 20(4):406-416.e11. PubMed ID: 35390767
[TBL] [Abstract][Full Text] [Related]
19. Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration.
Lakhani L; Alasfar S; Bhalla A; Aala A; Rosenberg A; Ostrander D; Schollenberger MD; Brennan DC; Lipson EJ
Transplant Direct; 2021 Feb; 7(2):e656. PubMed ID: 33490381
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
